Harvard Men's Health Watch

Cheaper treatment for vision loss just as safe as expensive option

An independent review of nine clinical trials found no clear difference in safety between two drugs for age-related vision loss, despite current practice to favor use of the more expensive drug because of safety concerns.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In